News & Perspective

Oct 17, 2006

Oct 17, 2006

Baxter says cell-based H5N1 vaccine shows potential in trial

(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.